243 related articles for article (PubMed ID: 15117992)
21. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of chimerism in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Furukawa T; Hashimoto S; Inano K; Yamazaki F; Takeda H; Kakihara T; Yano T; Abe T; Higuchi W; Toba K; Takahashi M; Koike T; Aizawa Y
Rinsho Ketsueki; 2001 Jun; 42(6):488-95. PubMed ID: 11505528
[TBL] [Abstract][Full Text] [Related]
23. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases.
Willasch A; Hoelle W; Kreyenberg H; Niethammer D; Handgretinger R; Lang P; Beck JF; Klingebiel T; Bader P
Haematologica; 2006 Jun; 91(6):788-94. PubMed ID: 16769581
[TBL] [Abstract][Full Text] [Related]
24. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia.
Yoshimi A; Niemeyer CM; Bohmer V; Duffner U; Strahm B; Kreyenberg H; Dilloo D; Zintl F; Claviez A; Wössmann W; Kremens B; Holter W; Niethammer D; Beck JF; Kontny U; Nöllke P; Klingebiel T; Bader P
Br J Haematol; 2005 May; 129(4):542-9. PubMed ID: 15877738
[TBL] [Abstract][Full Text] [Related]
25. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation.
Winiarski J; Mattsson J; Gustafsson A; Wester D; Borgström B; Ringdén O; Ljungman P; Dalianis T
Pediatr Transplant; 1998 May; 2(2):150-6. PubMed ID: 10082448
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Nagatoshi Y; Inada H; Nakayama H; Yanai F; Ayukawa H; Kawakami K; Moritake H; Suminoe A; Okamura J
Pediatr Blood Cancer; 2005 Aug; 45(2):111-20. PubMed ID: 15782402
[TBL] [Abstract][Full Text] [Related]
27. Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
Rettinger E; Merker M; Salzmann-Manrique E; Kreyenberg H; Krenn T; Dürken M; Faber J; Huenecke S; Cappel C; Bremm M; Willasch A; Bakhtiar S; Jarisch A; Soerensen J; Klingebiel T; Bader P
Biol Blood Marrow Transplant; 2017 Jan; 23(1):87-95. PubMed ID: 27742575
[TBL] [Abstract][Full Text] [Related]
28. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of donor cell chimerism for the detection of relapse and early immunotherapeutic intervention in acute lymphoblastic leukemias.
Bader P; Dückers G; Kreyenberg H; Hoelle W; Kerst G; Lang P; Greil J; Niethammer D; Beck LF; Klingebiel T
Ann Hematol; 2002; 81 Suppl 2():S25-7. PubMed ID: 12611064
[No Abstract] [Full Text] [Related]
30. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
31. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
32. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
34. Repetitive DNA polymorphisms in following chimerism after allogeneic bone marrow transplantation.
Grubic Z; Stingl K; Cecuk Jelicic E; Zunec R; Kastelan A; Serventi Seiwerth R; Bogdanic V; Labar B; Kerhin Brkljacic V
Clin Transplant; 2005 Oct; 19(5):586-90. PubMed ID: 16146548
[TBL] [Abstract][Full Text] [Related]
35. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
36. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?
Schilham MW; Balduzzi A; Bader P;
Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S49-52. PubMed ID: 15812531
[TBL] [Abstract][Full Text] [Related]
37. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
38. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
[TBL] [Abstract][Full Text] [Related]
39. Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia.
Mehta PA; Davies SM
Pediatr Blood Cancer; 2007 Jan; 48(1):1-2. PubMed ID: 16642487
[No Abstract] [Full Text] [Related]
40. Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients.
Pérez A; González-Vicent M; Ramirez M; Sevilla J; Madero L; Díaz MA
Br J Haematol; 2008 Feb; 140(3):340-3. PubMed ID: 18053071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
